Core Viewpoint - Perrigo reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59 per share, but showing an increase from $0.53 per share a year ago, indicating a -3.39% earnings surprise [1] - The company posted revenues of $1.06 billion for the quarter, missing the Zacks Consensus Estimate by 2.63%, and a slight decrease from $1.07 billion year-over-year [2] Financial Performance - Over the last four quarters, Perrigo has surpassed consensus EPS estimates two times [2] - The company has not been able to beat consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $1.12 billion, and for the current fiscal year, it is $3.04 on revenues of $4.44 billion [7] Stock Performance and Outlook - Perrigo shares have increased by approximately 3.5% since the beginning of the year, compared to the S&P 500's gain of 7.1% [3] - The company's earnings outlook and management's commentary on the earnings call will be crucial for future stock price movements [3][4] - The estimate revisions trend for Perrigo was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Products industry, to which Perrigo belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Cresco Labs Inc., is expected to report a quarterly loss of $0.04 per share, with revenues projected to decline by 11.1% year-over-year [9]

Industry Overview - The U.S. legal cannabis market is projected to reach approximately $45 billion by 2025 and grow at over 11.5% CAGR through 2030, potentially reaching about $76 billion [1] - North America holds nearly 82% of the market share, with over 440,000 full-time jobs supported by the legal cannabis sector [1] - A significant consumer trend shows that 1 in 3 women over 21 now consume cannabis, and 79% of Americans live in a county with at least one dispensary [1] Legislative Environment - Recent legislative efforts include the bipartisan PREPARE Act and the STATES 2.0 Act, which propose interstate commerce provisions [2] - The Supreme Court may address cannabis and gun ownership bans, and President Trump indicated that rescheduling could progress soon [2] - A California cultivation company faced scrutiny after a federal raid, highlighting both opportunities and risks in the cannabis sector [2] Company Profiles Curaleaf Holdings, Inc. (CURLF) - Curaleaf operates over 150 dispensaries across 19 states, with significant markets in Florida, New York, Massachusetts, and Arizona [3][4] - The company reported quarterly revenue of approximately $342 million, showing slight year-over-year growth, but posted a net loss of nearly $49 million due to increased operating expenses [8] - Curaleaf is focused on regulatory compliance and product safety, with a strategy aimed at scalability and national branding [9] Cresco Labs Inc. (CRLBF) - Cresco operates more than 70 dispensaries across 10 states, focusing on high-volume cannabis production and wholesale distribution [10] - The company generated quarterly revenue of approximately $195 million, with positive adjusted EBITDA and strong gross profit due to operational efficiencies [12] - Cresco's wholesale model and retail expansion support its long-term mission to become a leading cannabis brand [14] AYR Wellness Inc. (AYRWF) - AYR operates over 90 dispensaries, primarily in Florida, Pennsylvania, and Nevada, emphasizing vertical integration to control product quality [15][16] - The company reported revenue of roughly $118 million, achieving positive adjusted EBITDA for the fifth consecutive quarter, with improved gross margins [18] - AYR is focused on margin growth and cash flow stability, targeting additional licensing opportunities in underserved regions [19] Investment Outlook - Investors are monitoring Curaleaf for its market leadership and long-term potential, Cresco for its steady revenue and operational excellence, and AYR for its disciplined operations and quality-driven growth [20] - Each company is well-positioned to benefit from future legalization or regulatory easing, despite the current volatility in the cannabis sector [21]

分组1 - Exagen Inc. reported a quarterly loss of $0.18 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.16 per share a year ago [1] - The company posted revenues of $17.2 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 7.51%, and up from $15.06 million year-over-year [2] - Exagen shares have increased approximately 80.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] 分组2 - The earnings outlook for Exagen is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Exagen was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $16.5 million, and -$0.61 on revenues of $65.8 million for the current fiscal year [7] 分组3 - The Medical - Products industry, to which Exagen belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, which may impact stock performance [8] - Cresco Labs Inc., another company in the same industry, is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +75%, with revenues projected at $163.86 million, down 11.1% from the previous year [9]

Core Insights - The cannabis industry has seen a significant decline from $30 billion to approximately $4 billion, raising concerns for investors in marijuana stocks [1][2] - Federal reform is deemed necessary for the market to gain legitimacy, which historically has led to improved market momentum when such measures have been proposed [2] - Current market conditions have left investors uncertain, with some viewing the low prices as a potential buying opportunity for top marijuana stocks [3] Company Summaries - **Jushi Holdings Inc.**: A vertically integrated cannabis company involved in cultivation, processing, retail, and distribution for both medical and adult-use markets in the U.S. [4][5] - **Greenlane Holdings, Inc.**: Focuses on the development and distribution of cannabis accessories and lifestyle products across the U.S., Canada, Europe, and Latin America. Recently announced a partnership with JointCommerce for B2C e-commerce solutions [9][13] - **Cresco Labs Inc.**: Engaged in the cultivation and sale of retail and medical cannabis products. The company is undergoing a strategic restructuring, including the sale of its California operations to enhance its balance sheet and focus on high-margin markets [14][16]

Industry Overview - The legal cannabis industry in the USA has faced a continuous downtrend, with many marijuana stocks falling significantly, leading to challenges in profit-taking for investors [1] - Shareholders are adopting a long-term strategy, hoping for federal legalization and banking reforms to enhance the safety of their investments [2] - Speculation around better reforms and opportunities in international markets like Canada and Europe is driving interest in the cannabis sector [3] Company Highlights - **Trulieve Cannabis Corp.**: Operates as a cannabis retailer, cultivating, processing, and distributing cannabis products. Recently partnered with Redemption Cannabis to launch products in West Virginia [4][5] - **Curaleaf Holdings, Inc.**: Engaged in the production and distribution of cannabis products both domestically and internationally. Scheduled to report Q2 2025 financial earnings on August 6, 2025 [5][8] - **Cresco Labs Inc.**: Cultivates and sells retail and medical cannabis products. Recently changed its auditor from Marcum LLP to Baker Tilly US, LLP, with shareholder ratification planned for the next annual meeting [9] Stocks to Watch - Top marijuana stocks identified for potential investment include Trulieve Cannabis Corp., Curaleaf Holdings, Inc., and Cresco Labs Inc. [6]

Group 1: Earnings Performance - AdaptHealth Corp. reported quarterly earnings of $0.01 per share, matching the Zacks Consensus Estimate, compared to $0.02 per share a year ago [1] - The company posted revenues of $777.88 million for the quarter, exceeding the Zacks Consensus Estimate by 1.72%, but down from $792.5 million year-over-year [2] - Over the last four quarters, AdaptHealth has surpassed consensus EPS estimates three times [1][2] Group 2: Stock Performance and Outlook - AdaptHealth shares have declined approximately 8.6% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] - The company's earnings outlook will be crucial for future stock movements, with current consensus EPS estimates at $0.28 for the coming quarter and $1.12 for the current fiscal year [4][7] - The current Zacks Rank for AdaptHealth is 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Products industry, to which AdaptHealth belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]